BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 30529386)

  • 1. Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis.
    Fan Y; Bazai SK; Daian F; Arechederra M; Richelme S; Temiz NA; Yim A; Habermann BH; Dono R; Largaespada DA; Maina F
    J Hepatol; 2019 Mar; 70(3):470-482. PubMed ID: 30529386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
    Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
    Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Tschida BR; Temiz NA; Kuka TP; Lee LA; Riordan JD; Tierrablanca CA; Hullsiek R; Wagner S; Hudson WA; Linden MA; Amin K; Beckmann PJ; Heuer RA; Sarver AL; Yang JD; Roberts LR; Nadeau JH; Dupuy AJ; Keng VW; Largaespada DA
    Cancer Res; 2017 Dec; 77(23):6576-6588. PubMed ID: 28993411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.
    Arechederra M; Bazai SK; Abdouni A; Sequera C; Mead TJ; Richelme S; Daian F; Audebert S; Dono R; Lozano A; Gregoire D; Hibner U; Allende DS; Apte SS; Maina F
    J Hepatol; 2021 Apr; 74(4):893-906. PubMed ID: 33197513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases.
    Fan Y; Arechederra M; Richelme S; Daian F; Novello C; Calderaro J; Di Tommaso L; Morcrette G; Rebouissou S; Donadon M; Morenghi E; Zucman-Rossi J; Roncalli M; Dono R; Maina F
    Hepatology; 2017 Nov; 66(5):1644-1661. PubMed ID: 28586114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-Step Forward Genetic Screen in Mice Identifies Ral GTPase-Activating Proteins as Suppressors of Hepatocellular Carcinoma.
    Kodama T; Bard-Chapeau EA; Newberg JY; Kodama M; Rangel R; Yoshihara K; Ward JM; Jenkins NA; Copeland NG
    Gastroenterology; 2016 Aug; 151(2):324-337.e12. PubMed ID: 27178121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma in mice.
    Riordan JD; Feddersen CR; Tschida BR; Beckmann PJ; Keng VW; Linden MA; Amin K; Stipp CS; Largaespada DA; Dupuy AJ
    Hepatology; 2018 Mar; 67(3):924-939. PubMed ID: 28961327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sleeping Beauty insertional mutagenesis screen identifies the pro-metastatic roles of CNPY2 and ACTN2 in hepatocellular carcinoma tumor progression.
    Lo LH; Lam CY; To JC; Chiu CH; Keng VW
    Biochem Biophys Res Commun; 2021 Feb; 541():70-77. PubMed ID: 33482578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
    Matalkah F; Martin E; Zhao H; Agazie YM
    Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decorin deficiency promotes hepatic carcinogenesis.
    Horváth Z; Kovalszky I; Fullár A; Kiss K; Schaff Z; Iozzo RV; Baghy K
    Matrix Biol; 2014 Apr; 35():194-205. PubMed ID: 24361483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma.
    Kodama T; Newberg JY; Kodama M; Rangel R; Yoshihara K; Tien JC; Parsons PH; Wu H; Finegold MJ; Copeland NG; Jenkins NA
    Proc Natl Acad Sci U S A; 2016 Jun; 113(24):E3384-93. PubMed ID: 27247392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma.
    Ribback S; Che L; Pilo MG; Cigliano A; Latte G; Pes GM; Porcu A; Pascale RM; Li L; Qiao Y; Dombrowski F; Chen X; Calvisi DF
    Cell Cycle; 2018; 17(12):1496-1512. PubMed ID: 29965794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SRC-2-mediated coactivation of anti-tumorigenic target genes suppresses MYC-induced liver cancer.
    Suresh S; Durakoglugil D; Zhou X; Zhu B; Comerford SA; Xing C; Xie XJ; York B; O'Donnell KA
    PLoS Genet; 2017 Mar; 13(3):e1006650. PubMed ID: 28273073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-Mediated Anti-Tumorigenesis and Phagocytosis of Hepatocellular Carcinoma.
    Yang HD; Kim HS; Kim SY; Na MJ; Yang G; Eun JW; Wang HJ; Cheong JY; Park WS; Nam SW
    Hepatology; 2019 Oct; 70(4):1262-1279. PubMed ID: 30991448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clathrin switches transforming growth factor-β role to pro-tumorigenic in liver cancer.
    Caballero-Díaz D; Bertran E; Peñuelas-Haro I; Moreno-Càceres J; Malfettone A; López-Luque J; Addante A; Herrera B; Sánchez A; Alay A; Solé X; Serrano T; Ramos E; Fabregat I
    J Hepatol; 2020 Jan; 72(1):125-134. PubMed ID: 31562907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The DNA methylation profile of liver tumors in C3H mice and identification of differentially methylated regions involved in the regulation of tumorigenic genes.
    Matsushita J; Okamura K; Nakabayashi K; Suzuki T; Horibe Y; Kawai T; Sakurai T; Yamashita S; Higami Y; Ichihara G; Hata K; Nohara K
    BMC Cancer; 2018 Mar; 18(1):317. PubMed ID: 29566670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours.
    Nwosu ZC; Battello N; Rothley M; Piorońska W; Sitek B; Ebert MP; Hofmann U; Sleeman J; Wölfl S; Meyer C; Megger DA; Dooley S
    J Exp Clin Cancer Res; 2018 Sep; 37(1):211. PubMed ID: 30176945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mediator subunit 23 overexpression as a novel target for suppressing proliferation and tumorigenesis in hepatocellular carcinoma.
    Guo Y; Wang J; Li H; Liu W; Chen D; Zhao K; Liang X; Zhang Q; Yang Y; Chen G
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1094-103. PubMed ID: 25684393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer.
    O'Donnell KA; Keng VW; York B; Reineke EL; Seo D; Fan D; Silverstein KA; Schrum CT; Xie WR; Mularoni L; Wheelan SJ; Torbenson MS; O'Malley BW; Largaespada DA; Boeke JD
    Proc Natl Acad Sci U S A; 2012 May; 109(21):E1377-86. PubMed ID: 22556267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma.
    Chiu AP; Tschida BR; Lo LH; Moriarity BS; Rowlands DK; Largaespada DA; Keng VW
    World J Gastroenterol; 2015 Nov; 21(42):12157-70. PubMed ID: 26576100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.